CEO SUMMARY: For years, the adoption of digital pathology has lagged behind the predictions of its advocates. That has encouraged one digital pathology company—Inspirata, Inc., of Tampa—to come up with a different business strategy designed to help anatomic pathology labs address the barriers and capital costs involved with establishing a digital pathology system. The Ohio
In a milestone for advocates of digital pathology, n anatomic pathology laboratory in The Netherlands has been identified as the first in the world to “transition completely to digital diagnosis.” The laboratory is Laboratorium Pathologie Oost-Nederland (LabPON), located in Hengelo.
CEO SUMMARY: During 2010, the Medicare Physician Quality Reporting Initiative (PQRI) will pay a 2% bonus to pathologists who register and report data on 80% of their cases for the specified CPT codes. However, independent pathology laboratories still cannot participate in the PQRI program. Also, PSA, LLC, reports it can be challenging to audit the
CEO SUMMARY: Whole slide imaging (WSI) is a niche product today, but it offers the potential to redefine the practice of pathology. That’s the opinion of pathologists presenting at a digital pathology workshop last month. One pathologist explained how WSI significantly improves collaboration between pathologists and referring physicians. Another pathologist explained how regulators soon may
CEO SUMMARY: Early this month, the second annual Molecular Summit assembled molecular first movers and early adopters to discuss their efforts to integrate molecular imaging and molecular diagnostics in patient care. One clear message emerged from two days of presentations and discussion: a host of new technologies is ready for clinical introduction and is likely
CEO SUMMARY: Anatomic pathology has been conducted the same way for 100 years—but no longer at the University of Miami. Pathologists there are using microwave technology to cut processing speed by 90% and improve workflow. By producing faster diagnoses, the lab can report results on 80% of samples the same day that specimens are received.
CEO SUMMARY: Evidence is accumulating that tissue banking may be where the “rubber meets the road;” where pharma money funds technology enhancements that directly benefit the profession of pathology. Without question, the need by pharma, biotech, and genomic companies to access, analyze and understand the tissue of targeted subpopulations is creating an opportunity for savvy